Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.

ImmuneID, a US-based precision immunology company based on Harvard University and Johns Hopkins University research, has launched with $17m in funding from investors including Harvard-aligned venture capital firm Xfund. Longwood Fund led the round, which also included Arch Venture Partners, Pitango HealthTech and In-Q-Tel, the investment affiliate of the US intelligence community, as well as…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.